Yantai Lannacheng Biotechnology

Yantai Lannacheng Biotechnology Co., Ltd. (LNC) is a clinical-stage biopharmaceutical company established in 2021 as a joint venture between Yantai Dongcheng Pharmaceutical Group, a prominent Chinese nuclear medicine enterprise, and Professor Xiaoyuan (Shawn) Chen, an expert in molecular imaging and nanomedicine. The company focuses on the development and registration of first-in-class, integrated radiotheranostics for oncological applications.

LNC's business strategy centers on creating its own pipeline of proprietary drug assets and then out-licensing them to larger biopharmaceutical partners who manage late-stage trials and commercialization. The company has successfully raised significant capital to fund its research and development, including a Series B+ financing round of 300 million RMB in April 2024, led by Shenzhen Capital Group. This followed earlier Series A and B funding rounds in 2022 and 2023, respectively.

The company's core technology revolves around a proprietary "albumin binder-Evans blue modification" platform, which enhances the tumor retention and absorbed dose of radiopharmaceuticals, allowing for potentially reduced dosages and less frequent administration. LNC's product pipeline is built upon this platform and includes radioligands based on small molecules, peptides, and antibodies. These products target a variety of solid tumors, such as prostate cancer, gastric cancer, gliomas, and neuroendocrine tumors, by targeting proteins like Fibroblast Activation Protein (FAP) and Prostate-Specific Membrane Antigen (PSMA). Several of its candidates have received Investigational New Drug (IND) approvals from regulatory bodies in the US, Singapore, and China and are advancing through clinical trials.

To support its R&D, LNC invested over 100 million RMB to build a 6,500-square-meter comprehensive laboratory in Yantai's "MediPark," which became operational in 2023. This facility integrates drug synthesis, radiolabeling, preclinical studies, and molecular imaging, forming the company's core translational medicine platform. Headquartered in Yantai, the company also operates a subsidiary in Singapore, LNC Pharma Pte. Ltd., to manage international affairs.

Keywords: radiopharmaceuticals, theranostics, nuclear medicine, oncology, drug development, molecular imaging, nanomedicine, FAP inhibitors, PSMA targeting, albumin binders, radioligand therapy, cancer treatment, clinical trials, biopharmaceutical, Yantai Dongcheng Pharmaceutical, Xiaoyuan Chen, radiolabeling, targeted therapy, solid tumors, prostate cancer